We are live on ! Find out more

586 hedge funds and large institutions have $10.7B invested in Sanofi in 2021 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 231 increasing their positions, 156 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more call options, than puts

Call options by funds: $39M | Put options by funds: $17.6M

48% more repeat investments, than reductions

Existing positions increased: 231 | Existing positions reduced: 156

42% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 43

40% more funds holding in top 10

Funds holding in top 10: 57 (+2)

9% more capital invested

Capital invested by funds: $9.77B → $10.7B (+$919M)

2% more funds holding

Funds holding: 573586 (+13)

0.41% more ownership

Funds ownership: 15.65%16.06% (+0.41%)

Holders
586
Holders Change
+13
Holders Change %
+2.27%
% of All Funds
10.16%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.12%
New
61
Increased
231
Reduced
156
Closed
43
Calls
$39M
Puts
$17.6M
Net Calls
+$21.4M
Net Calls Change
-$5.11M

SNY Hedge Fund Activity: Q2 2021 in Review

586 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2021, worth a combined $10.7B — up 9.4% from $9.77B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new SNY positions and 43 closed out — a net gain of 18 holders — while 231 added to existing stakes and 156 trimmed.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $117M. The largest seller was Arrowstreet Capital, cutting an estimated $47.7M.

  • 586 institutional investors held Sanofi (SNY) as of Q2 2021, up from 573 in Q1 2021.
  • Funds reported $10.7B of Sanofi stock for Q2 2021, up 9.4% quarter-over-quarter.
  • 61 funds opened new Sanofi positions in Q2 2021 and 43 closed out, a net change of +18 holders.
  • The largest Sanofi buyer in Q2 2021 was Camber Capital Management, an estimated $117M added.
  • The largest Sanofi seller in Q2 2021 was Arrowstreet Capital, an estimated $47.7M sold.

Based on aggregated 13F filings for Q2 2021.